Drug Profile
Asp-B10
Latest Information Update: 23 Mar 2009
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Novo Nordisk
- Class Amino acids; Antihyperglycaemics; Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 23 Mar 2009 Discontinued for Diabetes mellitus in Denmark (SC)
- 23 Mar 2009 Discontinued for Diabetes mellitus in USA (SC)
- 26 Feb 2001 No-Development-Reported for Diabetes mellitus in USA (SC)